UroGen Pharma Ltd. (URGN)
26.39
+0.29
(+1.11%)
USD |
NASDAQ |
Nov 12, 16:00
26.77
+0.38
(+1.44%)
After-Hours: 20:00
UroGen Pharma Free Cash Flow (Quarterly) : -13.60M for Sept. 30, 2026
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -13.60M |
| June 30, 2026 | -35.08M |
| March 31, 2026 | -45.37M |
| December 31, 2025 | -42.53M |
| September 30, 2025 | -47.69M |
| June 30, 2025 | -40.31M |
| March 31, 2025 | -42.07M |
| December 31, 2024 | -13.98M |
| September 30, 2024 | -27.95M |
| June 30, 2024 | -23.39M |
| March 31, 2024 | -31.74M |
| December 31, 2023 | -12.04M |
| September 30, 2023 | -16.45M |
| June 30, 2023 | -19.57M |
| March 31, 2023 | -25.83M |
| December 31, 2022 | -20.51M |
| September 30, 2022 | -16.85M |
| June 30, 2022 | -23.17M |
| March 31, 2022 | -24.02M |
| Date | Value |
|---|---|
| December 31, 2021 | -21.91M |
| September 30, 2021 | -19.02M |
| June 30, 2021 | -19.09M |
| March 31, 2021 | -27.69M |
| December 31, 2020 | -23.40M |
| September 30, 2020 | -27.29M |
| June 30, 2020 | -24.11M |
| March 31, 2020 | -35.73M |
| December 31, 2019 | -26.64M |
| September 30, 2019 | -13.35M |
| June 30, 2019 | -14.81M |
| March 31, 2019 | -17.98M |
| December 31, 2018 | -9.800M |
| September 30, 2018 | -9.296M |
| June 30, 2018 | -7.990M |
| March 31, 2018 | -9.696M |
| December 31, 2017 | -6.358M |
| September 30, 2017 | 2.700M |
Free Cash Flow Definition
Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| Xencor, Inc. | 0.838M |
| MeiraGTx Holdings Plc | -38.87M |
| Ironwood Pharmaceuticals, Inc. | 67.40M |
| Viking Therapeutics, Inc. | -138.19M |
| IDEAYA Biosciences, Inc. | -93.75M |